RECURSION PHARMACEUTICALS, INC. 4

CEO and President Najat Khan sold 22,408 shares of Recursion Pharmaceuticals Class A Common Stock for about $3.52 per share under a Rule 10b5-1 plan.

On September 8, 2026, Najat Khan, CEO and President of Recursion Pharmaceuticals, Inc., sold 22,408 shares of the company’s Class A Common Stock at a weighted average price of approximately $3.52 per share under a pre-established Rule 10b5-1 trading plan. The sale, totaling roughly $78,800 in value, was executed in multiple trades within a price range of $3.485 to $3.58. Following this disposition, Khan continued to hold 2,072,890 shares of Class A Common Stock, indicating a substantial remaining equity stake in the company.

Filing Facts

CIK

1601830

Ticker

RXRX

Form

4

Source Type

fda

Accession

0001601830-26-000105

Alert Tier

5